நரம்பியல் சிகிச்சை பரப்பளவு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நரம்பியல் சிகிச்சை பரப்பளவு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நரம்பியல் சிகிச்சை பரப்பளவு Today - Breaking & Trending Today

Takeda organiza una conferencia telefónica sobre sus productos en desarrollo Wave 1 - Iberonews


Takeda organiza una conferencia telefónica sobre sus productos en desarrollo Wave 1
CAMBRIDGE, Mass. y OSAKA, Japón (BUSINESS WIRE)
Takeda Pharmaceutical Company Limited
(TSE:4502/NYSE:TAK) (“Takeda”) ha anunciado hoy que realizará una conferencia telefónica el 6 de abril de 2021 para informar sobre las nuevas entidades moleculares (NEM) seleccionadas en su cartera de productos en desarrollo Wave 1. Con varias presentaciones de NEM ante las autoridades normativas previstas para fines del ejercicio fiscal 2021, la compañía mencionará sus planes para el crecimiento orgánico y sostenible de los ingresos durante los próximos años.
Texto completo a continuación ....

Sarah Sheikh , Christophe Weber , Ramona Sequeira , Claus Jepsen , Erika Gill , Elena Koundourakis , Panel Qa Session , Orexin Franchise Development , Innovative Pipeline , Select Wave , Potential Game Changer , Post Transplant Cytomegalovirus , Rare Genetic , Hematology Therapeutic Area , Global Product , Launch Strategy , Novel Moa , Dravet Syndrome , Neuroscience Therapeutic Area , Neuroscience Therapeutic , Franchise Strategy Update , First Potential Medicine , Underlying Disease , Narcolepsy Type , Global Portfolio , சாரா ஷேக் ,

Redirecting to Takeda Hosts Wave 1 Pipeline Market Call


9:00 p.m. – 9:05 p.m.
Introduction
8:05 a.m. – 8:10 a.m.
9:05 p.m. – 9:10 p.m.
Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs
Andy Plump, president of Research and Development
8:10 a.m. – 8:35 a.m.
9:10 p.m. – 9:35 p.m.
Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection
Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit
Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit
8:35 a.m. – 8:40a.m.
9:35 p.m. – 9:40p.m.
Break
9:40 p.m. – 10:00 p.m.
Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome ....

United States , Sarah Sheikh , Christophe Weber , Ramona Sequeira , Claus Jepsen , Erika Gill , Elena Koundourakis , Exchange Commission , Panel Qa Session , Takeda Pharmaceutical Company Limited , Orexin Franchise Development , Takeda Pharmaceutical Company , New Molecular Entities , Innovative Pipeline , Select Wave , Potential Game Changer , Post Transplant Cytomegalovirus , Rare Genetic , Hematology Therapeutic Area , Global Product , Launch Strategy , Novel Moa , Dravet Syndrome , Neuroscience Therapeutic Area , Neuroscience Therapeutic , Franchise Strategy Update ,

Exicure Announces Appointments of Elizabeth Garofalo, M.D., and Andrew Sassine to Its Board of Directors


Share:
Exicure, Inc. (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.
We are pleased to welcome Betsy and Andrew to our Board at a critical time for Exicure, having made significant progress with the development of cavrotolimod in oncology and XCUR-FXN in Friedreich s ataxia. Betsy s distinguished career and significant clinical development experience and Andrew s financial and institutional investor experience will provide important perspective to our Board, said Timothy P. Walbert, Exicure s Chairman of the Board of Directors. We look forward to the collective experience they will bring as Exicure advances its pipeline of innovative investigational therapies and we look to deliver on the promise of Exicure s proprietary Spherical Nucleic Acid, or SNA technology. ....

Ann Arbor , United States , United Kingdom , Wharton School , Andrew Sassine , David Walt , David Giljohann , Elizabeth Betsy Garofalo , Timothyp Walbert , Fidelity Investments , Board Of Acadia Pharmaceuticals Inc , Indiana University School Of Medicine , Institute For Advanced Clinical Trials In Children , Exicure Inc , Fidelity Small Cap Stock Fund , University Of Michigan Medical School , Icad Inc , Global Development Leadership Team , Pharma Consulting , Exchange Commission , University Of Pennsylvania , Fidelity International Small Cap Opportunities Fund , Global Head Of Clinical Development For Novartis , Spherical Nucleic Acid , Senior Vice President , Global Head ,